INTERVIEW WITH ALICIA MORGANS
Prostate Cancer Awareness Month September 2019 - US TOO SEA Blue Event

INTERVIEW WITH CHARLES RYAN
APCCC 2019 Global vs. Expert Consensus in the Management of Advanced Prostate Cancer Study

INTERVIEW WITH SILKE GILLESSEN & AURELIUS OMLIN
The Side Effects of Advanced Prostate Cancer Consensus Conference 2019 (APCCC)

INTERVIEW WITH JAMES GULLEY
Immunotherapy Across Genitourinary Malignancies

Videos
State-of-the-industry video lectures by leading urology experts
Featured Videos

EAU 2014 - Long-term immunotherapy by dendritic-cells based vaccine in patients with PSA-recurrent prostate cancer - Session Highlights

STOCKHOLM, SWEDEN (UroToday.com) - In this study, the group performed a phase I/II clinical trial of dendritic cell-based immunotherapy in prostate cancer patients with biochemical recurrence (BR). Primary goal of their study was to assess the safety, with secondary goals being PSA kinetics and presence of tumor antigen-specific immune response in the peripheral blood. They included 20 patients who showed BR after radical prostatectomy and salvage radiotherapy. Study medication consisted of 12 doses of 1x107 dendritic cells pulsed with killed prostate cancer cell line LNCap (DCVAC/PCa), injected subcutaneously in 4-weeks intervals.

eauThey reported that administration of DCVAC/PCa did not cause any significant side effects among 20 patients. Continuous cancer immunotherapy by DCVAC/PCa significantly prolonged the PSA doubling time (PSA-DT) in all treated patients (mean 3.43 fold increase). Seven of 20 patients had stable PSA levels during the course of treatment. Mean PSA-DT increased from 8.15 months before the initiation of cancer immunotherapy to 52.64 months at the completion of 12 doses (p < 0.0015). Moreover, sustained T cell responses against PSA, NY-ESO1, MAGE A1, and MAGE A3 were detected in the peripheral blood of enrolled patients.

In prostate cancer, using ultrasensitive PSA, the effect of cancer immunotherapy at the minimal residual disease stage can be evaluated in patients with biochemical recurrence. In this study, authors show that continuous cancer immunotherapy with dendritic cells, loaded with killed LNCAP cell line, can potentially be a mode of treatment for prostate cancer patients with biochemical recurrence.

Presented by L. J. Jarolim at the 29th Annual European Association of Urology (EAU) Congress - April 11 - 15, 2014 - Stockholmsmässan - Stockholm, Sweden.

Charles University, Department of Urology, Prague 5, Czech Republic

Written by Reza Mehrazin, MD, medical writer for UroToday.com

 

Conference Coverage
 
Recent data from conferences worldwide
Journals
Publications focusing on urologic cancer treatments through original manuscripts
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe